Campath
information and resources from the National Cancer Institute
NCI Thesaurus | Campath
(Other name for: alemtuzumab)NCI Thesaurus | Campath
(Other name for: alemtuzumab)
Alemtuzumab
Accel. Approv. (clinical benefit not established) Campath is indicated for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy.
Millennium and ILEX Partners, LP May 07 2001
|
|
|
|
news articles
BTG Announces Close Period Update Mar 31, 2006
PharmaLive.com (press release), Significant progress has also been made with products under development by licensees, including Campath®, for which encouraging efficacy results were obtained ...
UWE helps fight leukaemia with research into ‘natural killer’ ... Mar 8, 2006
innovations report, In Bristol a monoclonal antibody called Campath is used to kill donor T-cells, reducing the chance of GvHD. A side effect of Campath ...
German Pharma Powerhouse Potential Mar 13, 2006
BusinessWeek ...cancer. Schering brings its blood-cancer drugs Leukine and Campath to the table. Merck would also gain access to new markets. Schering ...
Mayor begins cancer therapy Mar 10, 2006
Atlanta Journal Constitution (subscription), Mayor Bobby Sikes is receiving a Campath treatment instead of chemotherapy. ... He is receiving a Campath treatment instead of chemotherapy, his son said. ...
Chest Service, Erasme University Hospital, Brussels, Belgium; and ... Mar 7, 2006
AJRCCM (subscription), In a phase I–II study, McCurry and colleagues treated 48 patients with either Campath-1H (alemtuzumab) or Thymoglobulin (antilymphoid antibody preparation ...
Drugs trial system 'must be reviewed' Mar 19, 2006
Manchester Evening News, Very few monoclonal antibodies exist that stimulate receptors, one exception being Campath, a last resort treatment for leukaemia. ...
Zacks.com announces that Nadine Wong highlights: Genzyme Mar 22, 2006
Business Wire (press release), Other ongoing initiatives are Campath for multiple sclerosis, televomer carbonate for C. difficile-associated diarrhea, DX88 for hereditary angioedema, and ...
US FDA issues warning on Schering's MS drug Campath Dec 1, 2005
Forbes FRANKFURT (AFX) - The US Food and Drug Administration has issued a warning on the use of Schering AG's multiple sclerosis drug Campath. ...
UPDATE 1-Schering shares fall on FDA alert over Campath Dec 1, 2005
Reuters Schering (SCHG.DE: Quote, Profile, Research) fell as much as 1.1 percent on Thursday after US regulators issued a health alert over its Campath drug in a trial ...
FDA: Alemtuzumab (marketed as Campath) Information Nov 30, 2005
PharmaLive.com (press release), 30, 2005-Three patients in a clinical study of the drug Campath for the treatment of Multiple Sclerosis (MS) developed severe idiopathic thrombocytopenic ...
FDA Sends Out Alert about Alemtuzumab (Campath) Dec 1, 2005
DG News ROCKVILLE, MD -- December 1, 2005 -- Three patients in a clinical study of the drug Campath (alemtuzumab) for the treatment of multiple sclerosis (MS ...
Schering's Campath News Not Detrimental Dec 1, 2005
New Ratings 0753 GMT [Dow Jones] The FDA's warning for Schering's (SHR) Campath drug isn'ta major shocker, as this is a normal occurrence during a testing phase, says ...
Schering's Campath Warning No Surprise Dec 1, 2005
New Ratings 1159 GMT [Dow Jones] The FDA's warning regarding Schering's (SHR) Campath drug doesn't come as a surprise, says MM Warburg. Points ...
Schering Unlikely To Plummet On Campath News Dec 1, 2005
New Ratings 0705 GMT [Dow Jones] Schering (SHR) seen lower intraday after the FDA's warning against the use of its Campath drug on patients with multiple sclerosis, say ...
Treatment with Subcutaneous (SC) MabCampath(R) (alemtuzumab) is ... Dec 12, 2005
PR Newswire UK (press release), The overall response rate for MabCampath and fludarabine therapy was 44 percent (39 percent with Campath alone); with three patients in the MabCampath ...
Schering says US FDA warning will have no impact on Campath sales ... Dec 1, 2005
Forbes AFX) - Schering AG's said a warning issued by the US Food and Drug Administration on the use of the company's multiple sclerosis drug Campath will have no ...
US FDA warns about Genzyme drug in MS trial Nov 30, 2005
Reuters ...(GENZ.O: Quote, Profile, Research) and Schering AG's (SCHG.DE: Quote, Profile, Research) drug Campath in a clinical trial to treat multiple sclerosis. ...
UPDATE 1-US FDA warns about Genzyme drug in MS trial Nov 30, 2005
Reuters ...(GENZ.O: Quote, Profile, Research) and Schering AG's (SCHG.DE: Quote, Profile, Research) drug, Campath, in a clinical trial to treat multiple sclerosis. ...
Schering shares fall on FDA alert Dec 1, 2005
MSN Money Reuters) - Shares in German drugmaker Schering fell as much as 1.1 percent on Thursday after US regulators issued a health alert over its Campath drug in a ...
Genzyme gets FDA warning on MS treatment Dec 1, 2005
Boston Business Journal, Genzyme Corp. suffered another setback to its bid to use its leukemia drug Campath to treat multiple sclerosis. The US Food and ...
New Study Reinforces Increased Life Expectancy with MabCampath(R) ... Dec 13, 2005
PR Newswire UK (press release), MabCampath, also marketed as Campath(R) in the United States, is the first and only humanized monoclonal antibody approved for CLL and the first drug with ...
HVB Keeps Schering At Outperform Dec 1, 2005
New Ratings 0959 GMT [Dow Jones] HVB keeps Schering (SHR) at outperform with a EUR57 target following the FDA's warning against the Campath use in multiple sclerosis, or MS ...
HVB Keeps Schering At Outperform >SHR Dec 2, 2005
New Ratings Points to Campath and ZK EPO projects, among others. Has EUR59 price target. Shares flat at EUR55.35. (JUM). Contact us in London. ...
BRA receives 3 proposals for Charlestown Armory Dec 1, 2005
Boston Globe, The Food and Drug Administration warned against the use of Campath for patients with multiple sclerosis. Campath is comarketed by Genzyme Corp. ...
European Stocks Such as ThyssenKrupp May Gain; Vivendi May Fall Nov 30, 2005
Bloomberg Genzyme Corp. and Schering's Campath drug for multiple sclerosis after a patient died from abnormal bleeding in clinical testing. Egg ...
US Stock Futures Rise as Oil Falls; Aeropostale Shares Gain Dec 1, 2005
Bloomberg Campath, a drug developed by Genzyme and Schering AG for multiple sclerosis, may have caused a patient to die in clinical testing, the US Food and Drug ...
European Indexes Up at Midday Dec 1, 2005
BusinessWeek Schering (SHR )(+0.38%) underperformed slightly after an FDA health alert on Campath usage in a clinical trial to treat multiple sclerosis. ...
New pancreas offers new life Nov 28, 2005
Boston Globe, While others use a combination of three drugs, including steroids, doctors in Lebanon use just one drug, called Campath, which has fewer side effects, Axelrod ...
On the Move: Prudential, Allianz, France Telecom Dec 1, 2005
BusinessWeek The FDA issued a health alert on Campath usage in a clinical trial to treat multiple sclerosis after three patients developed a severe blood disorder and one ...
|
|
